159 related articles for article (PubMed ID: 11660587)
1. Corporate corruption of medical literature: asbestos studies concealed by W.R. Grace & Co.
Egilman D; Wallace W; Hom C
Account Res; 1998 Jan; 6(1-2):127-47. PubMed ID: 11660587
[No Abstract] [Full Text] [Related]
2. Criminal liability for misconduct in scientific research.
Kuzma SM
Univ Mich J Law Reform; 1992; 25(2):357-421. PubMed ID: 11651584
[No Abstract] [Full Text] [Related]
3. Ethical oxymora for risk assessment practitioners.
Greenberg MR; Spiro H; McIntyre R
Account Res; 1991; 1(4):245-57. PubMed ID: 11651458
[No Abstract] [Full Text] [Related]
4. The toxicity/safety of processed free glutamic acid (MSG): a study in suppression of information.
Samuels A
Account Res; 1999; 6(4):259-310. PubMed ID: 11657840
[No Abstract] [Full Text] [Related]
5. Biological monitoring: the employer's dilemma.
Miller FH
Am J Law Med; 1984; 9(4):388-426. PubMed ID: 11644166
[No Abstract] [Full Text] [Related]
6. Bioethics and applied biomaterials.
Saha S; Saha P
J Biomed Mater Res; 1987 Aug; 21(Suppl. A2):181-90. PubMed ID: 11649924
[No Abstract] [Full Text] [Related]
7. Compensation for and prevention of occupational disease.
American Public Health Association
Am J Public Health; 1984 Mar; 74(3):292-5. PubMed ID: 11644114
[TBL] [Abstract][Full Text] [Related]
8. Occupational health risks and the worker's right to know.
Yale Law J; 1981 Jul; 90(8):1792-810. PubMed ID: 11658346
[No Abstract] [Full Text] [Related]
9. Pitching doctors.
Wilkes MS; Shuchman M
N Y Times Mag; 1989 Nov; ():88, 90, 126, 128-129. PubMed ID: 11650264
[No Abstract] [Full Text] [Related]
10. The regulation of human experimentation in the United States--a personal odyssey.
Katz J
IRB; 1987; 9(1):1-6. PubMed ID: 11649890
[No Abstract] [Full Text] [Related]
11. Legal and regulatory perspectives in mass immunization programs.
Ladimer I
Insur Law J; 1976 Aug; (643):. PubMed ID: 11664613
[No Abstract] [Full Text] [Related]
12. Health Research Extension Act of 1985. Public Law 99-158.
United States
US Statut Large; 1985; 99(Title IV Sections 1-12):. PubMed ID: 11686169
[No Abstract] [Full Text] [Related]
13. First federal agency to now require treatment for injured research subjects.
Maloney DM
Hum Res Rep; 1998 Apr; 13(4):1-2. PubMed ID: 11656896
[No Abstract] [Full Text] [Related]
14. Money is putting people at risk in biomedical research.
Andrews LB
Chron High Educ; 2000 Mar; 46(27):B1, B4-5. PubMed ID: 11657699
[No Abstract] [Full Text] [Related]
15. Risky alliance on medicine's cutting edge: firm faces business, ethics issues in NIH joint venture.
Lehrman S
Washington Post; 1991 Aug; ():Business 1, 14. PubMed ID: 11646923
[No Abstract] [Full Text] [Related]
16. FDA issues concerning conflicts of interest.
Kurt TL
IRB; 1990; 12(5):6-9. PubMed ID: 11654003
[No Abstract] [Full Text] [Related]
17. Conference report on S. 540, a bill to amend the Public Health Service Act to establish a National Institute of Arthritis and Musculoskeletal and Skin Diseases, and for other purposes.
Dingell JD
Congr Rec (Dly Ed); 1984 Oct; 130(131):H11339-60. PubMed ID: 11658583
[No Abstract] [Full Text] [Related]
18. The cold war experiments.
Budiansky S; Goode EE; Gest T
US News World Rep; 1994 Jan; 116(3):32-34, 36, 38. PubMed ID: 11659685
[No Abstract] [Full Text] [Related]
19. Policing fraud and deceit: the legal aspects of misconduct in scientific inquiry.
Protti M
J Infor Ethics; 1996; 5(1):59-71. PubMed ID: 11653390
[No Abstract] [Full Text] [Related]
20. The role of the federal government in protecting citizens from communicable diseases.
Morgenstern MS
Univ Cincinnati Law Rev; 1978; 47(4):537-71. PubMed ID: 11664964
[No Abstract] [Full Text] [Related]
[Next] [New Search]
